Featured Research

from universities, journals, and other organizations

Stents linked to low major adverse coronary events

Date:
October 30, 2013
Source:
Cardiovascular Research Foundation
Summary:
A new study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible polymer stents in patients undergoing percutaneous coronary intervention.

A new study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible polymer stents in patients undergoing percutaneous coronary intervention (PCI). The findings of the SORT-OUT VI trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Related Articles


Compared with bare metal stents, first generation DES reduced the risk of restenosis. However, the risk of stent thrombosis was a concern and newer generation DES have been designed to improve efficacy, safety, and device performance. To date, there are no large scale randomized comparison studies of biodegradable polymer-coated stents and biocompatible polymer-coated stents in all-comer populations. The SORT-OUT VI trial investigated the safety and efficacy of a durable but biocompatible polymer coated zotarolimus-eluting stent compared with a biodegradable polymer-coated biolimus-eluting stent in a population-based setting.

SORT-OUT VI was a multicenter, all-comer, non-inferiority trial that randomized 2,999 patients with stable coronary artery disease or acute coronary syndromes. The trial was performed within the framework of the Scandinavian Organization for Randomized Trials with Clinical Outcomes, and used patient-driven clinical event detection through Danish health care registries.

Patients were randomized to receive either a zotarolimus-eluting permanent polymer stent (n=1,502) or a biolimus-eluting biodegradable stent (n=1,497). The primary endpoint was a composite of major adverse cardiac events including cardiac death, myocardial infarction, and target lesion revascularization after 12 months.

After 12 months the percentage of patients with major adverse cardiac events was similarly low in both the zotarolimus-eluting and biolimus-eluting stent groups (5.3 percent and 5.1 percent, respectively), demonstrating the non-inferiority of the zotarolimus-eluting stent.

"The SORT OUT VI trial found that both zotarolimus-eluting and the biolimus-eluting stents were associated with low major adverse cardiac events," said lead investigator Bent Raungaard MD. Dr. Raungaard is Chief Physician and Associate Professor at Aalborg University Hospital in Denmark.

"Further, the zotarolimus-eluting stent was found to be non-inferior to the biolimus-eluting stent for patients treated with PCI."


Story Source:

The above story is based on materials provided by Cardiovascular Research Foundation. Note: Materials may be edited for content and length.


Cite This Page:

Cardiovascular Research Foundation. "Stents linked to low major adverse coronary events." ScienceDaily. ScienceDaily, 30 October 2013. <www.sciencedaily.com/releases/2013/10/131030093218.htm>.
Cardiovascular Research Foundation. (2013, October 30). Stents linked to low major adverse coronary events. ScienceDaily. Retrieved January 31, 2015 from www.sciencedaily.com/releases/2013/10/131030093218.htm
Cardiovascular Research Foundation. "Stents linked to low major adverse coronary events." ScienceDaily. www.sciencedaily.com/releases/2013/10/131030093218.htm (accessed January 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, January 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC: Get Vaccinated for Measles

CDC: Get Vaccinated for Measles

Reuters - US Online Video (Jan. 30, 2015) The CDC is urging people to get vaccinated for measles amid an outbreak that began at Disneyland and has now infected more than 90 people. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Obama To Outline New Plan For Personalized Medicine

Obama To Outline New Plan For Personalized Medicine

Newsy (Jan. 30, 2015) President Obama is expected to speak with drugmakers Friday about his Precision Medicine Initiative first introduced last week. Video provided by Newsy
Powered by NewsLook.com
NFL Concussions Down; Still on Parents' Minds

NFL Concussions Down; Still on Parents' Minds

AP (Jan. 30, 2015) The NFL announced this week that the number of game concussions dropped by a quarter over last season. Still, the dangers of the sport still weigh on players, and parents&apos; minds. (Jan. 30) Video provided by AP
Powered by NewsLook.com
U.S. Wants to Analyze DNA from 1 Million People

U.S. Wants to Analyze DNA from 1 Million People

Reuters - US Online Video (Jan. 30, 2015) The U.S. has proposed analyzing genetic information from more than 1 million American volunteers to learn how genetic variants affect health and disease. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins